Publications by authors named "Larisa Savrasova"
Article Synopsis
- The text discusses the impact of pneumococcal conjugate vaccines (PCVs), specifically PCV10 and PCV13, on invasive pneumococcal disease (IPD) globally, highlighting how these vaccines have reduced the prevalence of disease caused by vaccine-type serotypes after extensive use.
- It describes the methodology of data collection from various surveillance sites, which aimed to evaluate IPD cases that occurred five years after the vaccines were implemented, focusing on different age groups for analysis.
- Findings indicate significant differences in serotype distribution between PCV10 and PCV13 sites; notably, certain serotypes, such as 19A and serotype 3, were prevalent in specific age groups, signaling ongoing challenges in controlling
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis.
Lancet Infect Dis
December 2024
Background: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages.
Methods: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%.
In 2010 in Latvia, invasive pneumococcal disease (IPD) became a cause for concern and vaccination of infants with four doses of 7-valent pneumococcal conjugate vaccine (PCV7) commenced. In 2012, 10-valent pneumococcal conjugate vaccine (PCV10) (three doses at 2, 4, and 12-15 month of age) vaccination was introduced. We described incidence and serotype distribution of IPD in Latvia and investigated serotypes associated with death from IPD based on surveillance data.
View Article and Find Full Text PDFGlobal Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.
Microorganisms
April 2021
Article Synopsis
- The PSERENADE project focuses on global surveillance of invasive pneumococcal disease (IPD) to assess the impact of pneumococcal conjugate vaccines (PCV10/13).
- Among 138 countries using PCV10/13 as of 2018, 109 had IPD surveillance systems, with data collected from 76, enabling a comprehensive analysis of 240,639 post-vaccine IPD cases.
- The dataset will aid in understanding the effectiveness of the vaccines across different demographics and vaccination schedules, influencing future immunization policies globally and nationally.
Article Synopsis
- The introduction of pneumococcal conjugate vaccines (PCVs) has significantly decreased the cases of pneumococcal meningitis, especially in countries that have used PCV10/13 for several years.
- A project called PSERENADE analyzed the types of pneumococcal strains still causing meningitis and found that certain serotypes, such as 19A and 6C, are still prevalent, particularly in older age groups.
- Current research on higher-valency PCVs could potentially address the remaining cases of pneumococcal meningitis, but further investigation is needed to understand their effectiveness in regions like the African meningitis belt.
Article Synopsis
- Serotype 1 (ST1) was a major cause of invasive pneumococcal disease (IPD) before the introduction of pneumococcal conjugate vaccines (PCVs), which include ST1 antigen.
- The PSERENADE project analyzed global data on ST1 IPD to assess the impact of PCV10/13 on disease rates, using advanced statistical methods.
- Results showed that after six years of using PCV10/13, there was a 95% reduction in ST1 IPD incidence across all age groups, but there is a need for more data from countries heavily affected by ST1 to improve the findings' applicability.
The Global Meningococcal Initiative (GMI) aims to prevent invasive meningococcal disease (IMD) worldwide through education, research and cooperation. In March 2019, a GMI meeting was held with a multidisciplinary group of experts and representatives from countries within Eastern Europe. Across the countries represented, IMD surveillance is largely in place, with incidence declining in recent decades and now generally at <1 case per 100,000 persons per year.
View Article and Find Full Text PDF